Immunocore Holdings (NASDAQ:IMCR) Q2 2022 Earnings Conference Call August 9, 2022 8:00 AM ET
Company Participants
Clayton Robertson - Head, IR
Bahija Jallal - CEO & Director
Brian Di Donato - CFO & Head, Strategy
Ralph Torbay - Head, Commercial
David Berman - Head, Research & Development
Conference Call Participants
Michael Yee - Jefferies
Jessica Fye - JPMorgan Chase & Co.
Tyler Van Buren - Cowen and Company
Justin Kim - Oppenheimer
Justin Zelin - BTIG
Matthew Phipps - William Blair & Company
Gil Blum - Needham & Company
Patrick Trucchio - H.C. Wainwright & Co.
Operator
Greetings. Welcome to the Immunocore Second Quarter 2022 Earnings Call. [Operator Instructions]. Please note, this conference is being recorded. I will now turn the conference over to your host, Clay Robertson, Head of Investor Relations. Thank you. You may begin.
Clayton Robertson
Thank you, Alex. Welcome to our Q2 earnings call. My name is Clayton Robertson, Head of Investor Relations at Immunocore. During today's call, we will be making forward-looking statements, including about financial projections, development activities, business strategy and the timing and impact of future events. Actual results could differ materially from those projected by these statements, which are based on management's views as of today, and subject to risks and uncertainties, including those noted in our most recent Form 20-F and in 6-K we filed with the SEC and in the earnings press release we issued this morning. You are cautioned not to place any undue reliance on these statements, and Immunocore disclaims any obligation to update them. We will also discuss certain non-IFRS measures on today's call, which are reconciled to the comparable IFRS measures in today's slides.
I'm now pleased to introduce Immunocore's Chief Executive Officer, Dr. Bahija Jallal.
Bahija Jallal
Thank you, Clay. Good morning and good afternoon, everyone. We are very happy to be here and to share our strong Q2 results with you. With me today are Brian Di Donato, our Chief Financial Officer and Head of Strategy; Ralph Torbay, our Head of Commercial; and Dr. David Berman, our Head of R&D.
Our platform is an off-the-shelf soluble bispecific T cell receptor that was validated in a positive Phase III trial. This was the first ever T cell engager to show overall survival in solid tumors. In January, we received the approval of our first product, KIMMTRAK. With that, we have pioneered the new therapeutic modality, but most importantly, we have opened a new chapter in the treatment of cancer. Having launched the world's first TCR therapeutic and with an industry-leading pipeline and platform, the potential for what we can deliver for patients and investors is tremendous. Thanks to the dedication of our team, we have had exceptional first half of 2022, and we are delivering, and I could not be more proud of all of them.